Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has demonstrated efficacy and tolerability in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Zhang, Shannon, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113513/
https://www.ncbi.nlm.nih.gov/pubmed/35592355
http://dx.doi.org/10.2147/LCTT.S360574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113513/
https://www.ncbi.nlm.nih.gov/pubmed/35592355
http://dx.doi.org/10.2147/LCTT.S360574

Ejemplares similares